LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that it has received notification that the NASDAQ Listing Qualifications Panel has determined to delist the company’s common stock from The NASDAQ Stock Market, effective with the open of the market on Thursday, May 14, 2009. The delisting is the result of the company’s failure to evidence a $35 million market value of listed shares for its common stock for 10 consecutive trading days or to regain compliance with one of the alternative listing criteria, including a shareholders’ equity of at least $2.5 million.
